Drugs / AIM-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01501942 | Feb 2012 → Feb 2013 | asthma | AIM Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIM-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01501942 ↗ |
| Known as | D-cyclohexylalanine-D-glutamic-glycine tripeptide | “AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide” NCT01501942 ↗ |
| Modality | Peptide | “AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide” NCT01501942 ↗ |
| Route | Oral | “AIM-102 is supplied as an oral solution.” NCT01501942 ↗ |